IP Library Granted Patent US 10,716,624
Granted Patent B2
US 10,716,624 · App. 13/101,873 · Granted Jul 21, 2020

Minimally invasive contraception method and device

Inventors: Martin Sabado (Haverhill, GB); Wolfgang Neuberger (Dubai, AE)
Assignee: Biolitec Unternehmensbeteiligungs II AG
A61B18/22A61B18/24A61B2018/00559A61B2018/00642A61B2018/00702A61B2018/00791A61B2018/00982A61B2090/378A61B2218/001
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,716,624
App. No.
13/101,873
Granted
Jul 21, 2020
Kind
B2
Abstract

Minimally invasive methods and devices for endoluminally treating female fallopian tubes or male vas deferens of mammals are presented as a permanent method of contraception. In preferred embodiments, medical devices for male and female sterilization comprise laser radiation source operating at one or more preselected wavelengths between about 980 nm and about 1950 nm, preferably at least one of 980 nm, 1470 nm and 1950 nm; treatment waveguide with a radial or cylindrical radiation emitting tip; viewing scope; and a temperature sensor. In another preferred embodiment, a minimally-invasive permanent contraception method for males and females comprises the steps of introducing at least one treatment waveguide in a body cavity; positioning the treatment waveguide inside a body cavity; irradiating; and repeating the procedure in companion body cavity to inhibit fertilization. In another embodiment, fluids are infused and/or extracted after, before or during the procedure to enhance laser energy absorption and enhance efficiency of laser treatment.

Claims (12)

1. A minimally-invasive permanent contraception method for male/female mammals comprising the steps of;

a) endoluminally introducing at least one treatment waveguide connected to a laser radiation source and having a radial or cylindrical laser radiation emitting tip, in a fallopian tube or vas deferens lumen;

b) positioning said at least one treatment waveguide in a preselected treatment site inside said fallopian tube or vas deferens lumen;

c) infusing into said fallopian tube or vas deferens lumen an infusion liquid selected as any substance/solution that can absorb the emitted radiation selected from the group of aqueous solutions, isotonic solutions, hypertonic solutions, hypotonic solutions, preselected chromophore solutions and combinations of these;

d) while progressively pulling back the treatment waveguide, endoluminally irradiating said fallopian tube or vas deferens lumen with laser radiation of at least two different wavelengths selected from the group consisting of 980+/−30 nm. 1470+/−50 nm and 1950+/−50 nm, the laser radiation having sufficient energy to denature proteins in said fallopian tube or vas deferens lumen, whereby a continuous linear endoluminal laser energy density is provided over an extended length of the fallopian tube or vas deferens;

e) using measurements from a temperature sensor to control irradiation of said fallopian tube or vas deferens lumen; said temperature sensor being disposed in proximity to the radial or cylindrical laser radiation emitting tip irradiating said fallopian tube or vas deferens lumen; and

f) repeating the procedure to achieve reduction or closure of the fallopian tube or vas deferens and thus inhibit fertilization.

2. The minimally-invasive permanent contraception method for male/female mammals according to claim 1 , wherein said step of positioning of treatment waveguide is performed under suitable imaging means selected from the group consisting of ultrasound, viewing scopes and combinations of them.

3. The minimally-invasive permanent contraception method for male/female mammals according to claim 1 , wherein said step of positioning of treatment waveguide comprises positioning of treatment waveguide using additional means selected from the group consisting of guide wires, introducer sheaths, catheters and combinations of them.

4. The medical minimally-invasive permanent contraception method for male/female mammals according to claim 1 , wherein said treatment waveguide is at least one optical fiber with a distal and a proximal end, and with a variable radiation emission section in the vicinity of its distal end.

5. The medical minimally-invasive permanent contraception method for male/female mammals according to claim 1 , wherein said radiation has wavelengths consisting of 980±30 nm and 1950±50 nm.

6. The medical minimally-invasive permanent contraception method for male/female mammals according to claim 1 , wherein the wavelengths of said radiation consist of 1470±50 nm and 1950±50 nm.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 23, 2016
From: BIOLITEC PHARMA MARKETING LTD.
To: BIOLITEC UNTERNEHMENSBETEILIGUNGS II AG
Reel/Frame 041182/0578 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 18, 2013
From: CERAMOPTEC INDUSTRIES, INC.
To: BIOLITEC PHARMA MARKETING LTD.
Reel/Frame 030245/0215 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 5, 2011
From: SABADO, MARTIN; NEUBERGER, WOLFGANG
To: CERAMOPTEC INDUSTRIES, INC.
Reel/Frame 026233/0194 →